Chronic Idiopathic Urticaria

The HCPLive chronic idiopathic urticaria page is a comprehensive resource for clinical news and insights on CIU. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Ligelizumab Improves Sleep and Disease Burden in CSU Patients

March 01, 2022

Article

The biologic sustained responses in managing sleep interference with numerically higher responses than omalizumab.

Overlapping Eosinophilic Diseases Linked to Greater Disease Burden in EoE Patients

February 28, 2022

Article

Investigators noted that the epidemiology and disease overlap among eosinophilic diseases are poorly understood.

BTK-Inhibition Considered for Dermatologic Conditions

February 21, 2022

Article

Investigators review the current understanding of the role of the BTK pathway and the potential value of pharmacological inhibition of BTK as a therapeutic strategy.

Phase 3 Trial on Dupilumab for Chronic Spontaneous Urticaria Stopped

February 18, 2022

Article

Dupilumab did not reach statistical significance in interim analysis despite numeric improvements being observed across key endpoints.

COVID-19 Linked to Exacerbations in Skin Diseases

September 15, 2021

Article

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

Ligelizumab and Omalizumab Optimal Treatments for Chronic Spontaneous Urticaria

August 26, 2021

Article

Investigators believe their study shows the efficacy and safety of the 2 biologic agents, which are known to have anti-inflammatory and immunosuppressant qualities.

Ligelizumab Superior to Omalizumab for Chronic Spontaneous Urticaria Clearance

April 25, 2021

Article

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.

FDA Allows for Omalizumab Self-Injection Across All Indications

April 12, 2021

Article

The approval of the sBLA means greater flexibility and reduced barriers in care during the pandemic.

FDA Sends Warning Letters for Illegal CBD Products

December 22, 2020

Article

The 5 companies issued letters will have 15 days to submit a compliance plan.

Orphan No More: A New Momentum for Pediatric Dermatology

December 16, 2020

Article

The FDA approvals of biologics for atopic dermatitis and psoriasis have ushered in a new era for the once-stagnant field of pediatric dermatology.

Latest News

FDA Approves Baloxavir Marboxil to Treat, Prevent Flu in Younger At-Risk Children

COVID-19 Vaccination Rates Lower in Adults with Vision, Hearing Disabilities

Kidney-Urinary Tract Involvement with Intermediate Junctional Epidermolysis Bullosa

View More News